Incubator: Akribion Genomics to focus on opportunities in therapeutics

BRAIN Biotech and TransCode Therapeutics join forces to develop a CRISPR-derived technology platform for cancer treatment

BRAIN Group’s Akribion Genomics business will prioritize the development of therapeutic applications within its CRISPR technology platform.

Change in the Executive Management Board of BRAIN Biotech AG, genome editing activities established under the Akribion Genomics brand.